[Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer].

Objective: To evaluate the effect of anthracycline pirarubicin-based regimen in association with different ways of fluorouracil (5-Fu) as neoadjuvant and adjuvant chemotherapy for primary breast cancer.

Methods: Two hundred and eighty-nine primary breast cancer patients who were to be operated, two to eight cycles of pirarubicin in association with cyclophosphamide and 5-Fu (CTF or CTFci regimen) were given before operation. The pathological response rate, effect and its relation with the infusion routes of 5-Fu were analyzed.

[Clinicopathologic characteristics and prognosis in young Chinese women with breast cancer].

Objective: To analyze the clinicopathologic characteristics and evaluate the prognosis in young Chinese women with breast cancer.

Methods: A total of 1538 female patients with operable primary breast cancer (stage I-III) treated at our hospital from December 1994 to December 2003 were analyzed retrospectively. Among them, 1075 patients (≤ 60 yrs) with the complete follow-up data were divided into two groups according to age: young breast cancer group (≤ 40 yrs, n = 208) and control group (41 - 60 yrs, n = 867) to analyze the differences in their clinicopathologic characteristics and evaluate the prognosis of both groups.

Breast cancer subtypes and survival in chinese women with operable primary breast cancer.

Objective: To investigate the associations between the different breast cancer subtypes and survival in Chinese women with operable primary breast cancer.

Methods: A total of 1538 Chinese women with operable primary breast cancer were analyzed in this study, the median follow-up was 77 months. Estrogen receptor (ER), progesterone receptor (PR), and HER2 status were available for these patients.

Current status of diagnosis and treatment of primary breast cancer in beijing, 2008.

Objective: To investigate the status of diagnosis and treatment of primary breast cancer in Beijing, 2008.

Methods: All the patients who were diagnosed as primary breast cancer in Beijing in 2008 were enrolled in this study. Information of these patients, including the features of tumors, clinical diagnosis and treatment was collected, and filled in the well-designed questionnaire forms by trained surveyors.

[The clinical research of local recurrence after breast-conserving therapy for breast cancer].

Objective: To compare and analyze the data of breast cancer recurrence after breast-conserving therapy (BCT), and to find high risk factors that can affect local recurrence.

Methods: A total of 1034 patients in the data base between January 2000 and June 2008 were analyzed retrospectively. The patients aged 23 to 94 years when diagnosed (median age, 48 years).

[Different influence of Her-2 expression on the prognosis in node-positive and node-negative breast cancer].

Objective: To investigate the prognostic significance of Her-2 expression in node-positive and node-negative breast cancer in Chinese women.

Methods: The Her-2 expression in breast cancers from 981 patients was detected by immunohistochemistry with anti-Her-2 (CB11) monoclonal antibody. The survival curves were analyzed by Kaplan-Meier method, and Cox regression model was applied to determine whether this factor is an independent predictor of survival in multivariate analysis.

Weekly paclitaxel improved pathologic response of primary chemotherapy compared with standard 3 weeks schedule in primary breast cancer.

The purpose of this study is to compare the efficacy of weekly paclitaxel to every-3-week schedule in terms of pathologic response and toxicity which caused treatment delay in primary chemotherapy of breast cancer. After pretreatment of two cycles of cyclophosphamide/ pirarubicin/ fluorouracil (cyclophosphamide 500 mg/m(2) days 1, 8; pirarubicin 35 mg/m(2) days 1, 8; 5-Fu 200 mg/m(2) day ci day 1-28, every 4 weeks), 219 women with histologically confirmed T(1-3) N(0-2) M(0) invasive breast cancer, whose vertical diameters production of breast tumor reduced not more than 75%, were randomized to receive four cycles of Pq3wC (arm A: paclitaxel 175 mg/m(2) day 1, carboplatin AUC 6 d1, every 3 weeks) or Pq1wC (arm B: paclitaxel 60 mg/m(2) days 1, 8, 15, carboplatin AUC 6 day 1 for every 3 weeks) before surgery, stratified by partial or no response (stable disease and progression of disease) evaluated by ultrasonography. Pathologic response of the primary tumor was assessed by using Miller and Payne grading system.

[Feasibility of predicting pathological evaluation by ultrasonic evaluation in initial stage of neoadjuvant chemotherapy for primary breast cancer].

Objective: To investigate the correlation between change of tumor size after 2 cycles of neoadjuvant chemotherapy and pathological evaluation after 4 cycles of neoadjuvant chemotherapy. And to evaluate the feasibility of predicting pathological evaluation by ultrasonic evaluation in the initial stage of neoadjuvant chemotherapy for primary breast cancer.

Methods: Retrospective analysis was performed in women with primary breast cancer, including 138 patients receiving 4 cycles of anthracycline-based neoadjuvant chemotherapy (CTX500 mg/m(2), D1, D8 Q28D; THP35 mg/m(2), D1, D8 Q28D; 5-Fu200 mg/m(2)/day.

[Correlation of BRCA1 and APC aberrant methylation with the response to anthracycline-based neoadjuvant chemotherapy in primary breast cancer].

Objective: To investigate the correlation of hypermethylation of BRCA1 and APC gene promoters with the response to anthracycline-based neoadjuvant chemotherapy in primary breast cancer.

Methods: One hundred and forty patients with primary breast cancer received anthracycline-based neoadjuvant chemotherapy, and pretreatment hypermethylation status of BRCA1 and APC genes promoters was detected by methylation-specific PCR.

Results: Of the 140 patients, 30 (21.

[Prognostic role of apoptosis-related gene Fas-1377 and -670 polymorphisms in breast cancer].

Objective: To investigate the correlations between Fas-1377 and -670 polymorphisms and survival in Chinese women with breast cancer.

Methods: Polymerase chain reaction-restriction fragment length polymorphism assay (PCR-RFLP) was used to detect the polymorphism of Fas gene in 310 breast cancer patients with a long-term follow-up (median 10.5 years, range 0.

[Management of non-malignant results in core needle biopsy of breast lesions].

Objective: To study the strategy of management of non-malignant results in core needle biopsy (CNB) of breast lesions.

Methods: Consecutive 2654 breast lesions underwent CNB with 14-gauge automated needles. 1130 lesions with diagnosis of non-malignant breast lesions examined by CNB were followed up.

[Role of ultrasound-guided needle biopsy of ultrasonographic abnormal axillary lymph nodes in patients with breast cancer].

Objective: To evaluate the utility of ultrasound (US)-guided needle biopsy of ultrasonographic abnormal axillary lymph nodes in the patients with breast cancer.

Methods: The pathological results of US-guided needle biopsy and clinical data of 395 primary breast cancer patients with ultrasonographic abnormal axillary nodes, all female, aged 24 - 83, were analyzed retrospectively.

Results: Node metastasis were detected in 277 (70.

[Ultrasound-guided core needle biopsy in the diagnosis of breast lesions].

Objective: To evaluate the accuracy and utility of ultrasound-guided core needle biopsy (CNB) in the diagnoses of breast lesions.

Methods: The clinical data of 2152 consecutive breast lesions examined by CNB were reviewed. The histological agreement between core pathology and subsequent excision pathology was studied.

[Association between hormone receptors and response to neoadjuvant anthracycline-based chemotherapy in breast cancer patients].

Objective: To investigate the associations between the hormone receptors, Ki67 expression and response to neoadjuvant anthracycline-based chemotherapy in breast cancer patients.

Methods: One hundred sixty-eight primary breast cancer patients received anthracycline-based neoadjuvant chemotherapy. The expression of estrogen receptor (ER), progesterone receptor (PR), and Ki67 were determined by immunohistochemistry assay in core-needle biopsy specimens prior to the chemotherapy, and pathologic response was assessed by Miller & Payne grade (G1 to G5).

[Breast-conserving therapy for centrally located primary breast cancer].

Objective: The goal of the study is to investigate the feasibility of breast-conserving therapy for early primary breast carcinoma centrally located in the breast.

Methods: 157 patients with stage I or II primary breast cancer located in the central part of the breast were operated with extended local excision and axillary lymph node dissection. Nipple-areola complex was excised in 18 patients.

[Preliminary study of new imaging agent, 99mTc-Rituximab, for sentinel lymph node biopsy of primary breast cancer].

Objective: To study the feasibility and effects of new imaging agent, 99mTc-Rituximab, for sentinel lymph nodes biopsy (SLNB) of primary breast cancer.

Methods: SLNB were performed in eighty-five primary breast cancer patients using 99mTc-Rituximab combined with patent blue. Metastases in sentinel lymph nodes were detected with routine pathologic and immunohistochemistry method.

[Clinical study of percutaneous ultrasound-guided or freehand core needle biopsy of primary breast cancer].

Objective: To evaluate ultrasound-guided or freehand percutaneous core needle biopsy in histopathological assessment of primary breast cancer lesions and its utility in primary breast cancer treatment.

Methods: Retrospectively analysis of the clinical data of 697 primary breast cancer examined by mean of core needle biopsy.

Results: The diagnostic accuracy, false negative rate and insufficiency rate was 90.

[The application of conservative surgery for local advanced and bigger primary breast carcinoma].

Objective: To discuss the application of conservative surgery for local advanced and bigger primary breast carcinoma (> 4 cm in diameter).

Methods: Thirty-three primary breast cancer patients with tumor diameter more than four centimeters were treated with wide local excision and axillary lymph node dissection. Before operation, neoadjuvant chemotherapy with anthracyclines based combined regimen was done in thirty-one patients.

[Exploration of the extent of axillary dissection for patients with node positive primary breast cancer].

Objective: To explore the frequency of the involvement of level III and interpectoral lymph nodes in patients with node-positive breast cancer, and discuss the necessity of completely axillary dissection in this subgroup of patients.

Methods: Consecutive 291 cases underwent completely axillary dissections (level I/II/III and interpectoral node) according to identical procedure. Level I/II, Level III and interpectoral lymph nodes were sent separately for routine pathological examination.

[Neoadjuvant chemotherapy for primary breast cancer].

Objective: To evaluate the feasibility and effect of fluorouracil (5-Fu) in association with anthracycline-based regimen as neoadjuvant chemotherapy for primary breast cancer.

Methods: For one hundred and eleven primary breast cancer patients with 114 lesions who were to be operated, two to six cycles of 5-Fu (continuous infusion) in association with epirubicin or pirarubicin and cyclophosphamide (CEFci or CTFci regimen) were given before operation. The response rate, side effect and its relation with tumor characteristics were studied.

[The early results of breast-conserving therapy in ninety-five patients of primary breast cancer].

Objective: To discuss the effects of breast-conserving therapy in Chinese women with early primary breast carcinoma.

Methods: Ninety-five patients with stage I to II primary breast cancer were operated with wide local excision and axillary lymph node dissection. After operation, the radiation therapy was done on the whole breast.